---
title: "Sector Update: Health Care Stocks Retreat Monday Afternoon"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277511276.md"
description: "Health care stocks fell on Monday, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) down 1.2%. The iShares Biotechnology ETF (IBB) decreased by 1.1%. Notably, uniQure (QURE) shares plummeted 33% after the FDA deemed their trial data insufficient for a marketing application for AMT-130. Zoetis (ZTS) announced a $160 million acquisition of Neogen's (NEOG) animal genomics business, while Gyre Therapeutics (GYRE) shares rose 7.4% following their agreement to acquire Cullgen for $300 million in stock."
datetime: "2026-03-02T19:02:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277511276.md)
  - [en](https://longbridge.com/en/news/277511276.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277511276.md)
---

# Sector Update: Health Care Stocks Retreat Monday Afternoon

02:02 PM EST, 03/02/2026 (MT Newswires) -- Health care stocks declined Monday afternoon with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each dropping 1.2%.

The iShares Biotechnology ETF (IBB) shed 1.1%.

In corporate news, uniQure (QURE) shares tumbled 33% after the US Food and Drug Administration said data from the company's Phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.

Zoetis ( ZTS ) agreed to buy Neogen's (NEOG) animal genomics business for $160 million. Neogen shares fell 0.7%, and Zoetis ( ZTS ) dropped 2%.

Gyre Therapeutics ( GYRE ) shares climbed 7.4% after the company agreed to acquire clinical-stage biopharmaceutical company Cullgen for $300 million in stock.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [QURE.US](https://longbridge.com/en/quote/QURE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [NEOG.US](https://longbridge.com/en/quote/NEOG.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [GYRE.US](https://longbridge.com/en/quote/GYRE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)

## Related News & Research

- [RBC Capital Sticks to Their Buy Rating for Edwards Lifesciences (EW)](https://longbridge.com/en/news/282768248.md)
- [Neogen (NEOG) Q3 Losses Keep Margin Concerns Central To Bullish Discount Narrative](https://longbridge.com/en/news/282392444.md)
- [Neogen beats Q3 revenue estimates, raises outlook](https://longbridge.com/en/news/282182658.md)
- [Neogen (NEOG) Q1 Earnings Report Preview: What To Look For](https://longbridge.com/en/news/281964444.md)
- [KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M](https://longbridge.com/en/news/282893053.md)